Skip to main content

Advertisement

SpringerLink
Log in

Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications

  • Palliative Medicine (A Jatoi, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Liver cancer is a major health burden globally with high rates in the Far East and Southeast Asia. Hepatitis B virus and hepatitis C virus remain the major causes of hepatocellular carcinoma (HCC) worldwide; however, the epidemiology is changing. Here, we review the changing epidemiological changes among Far East and Southeast Asians and among Asian Americans in the USA.

Recent Findings

HBV- and HCV-induced HCC is anticipated to decline in incidence. In contrast, nonalcoholic fatty liver disease-induced HCC will outrank viral hepatitis in the next decade. Alcoholic liver disease will remain a persistent risk factor for HCC. These epidemiological shifts might have implications for the care of patients with HCC as described in this review.

Summary

Societal changes are impacting the global incidence of HCC and will likely also impact the care of patients with this malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians.n/a(n/a).

  2. Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2020;126(10):2225–49.

    Article  PubMed  Google Scholar 

  3. Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, et al. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol Biol (Paris). 2010;58(4):278–87.

    Article  CAS  Google Scholar 

  4. Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122(22):3430–46.

    Article  PubMed  Google Scholar 

  5. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.

    Article  CAS  PubMed  Google Scholar 

  6. Chimed T, Sandagdorj T, Znaor A, Laversanne M, Tseveen B, Genden P, et al. Cancer incidence and cancer control in Mongolia: results from the National Cancer Registry 2008–12. Int J Cancer. 2017;140(2):302–9.

    Article  CAS  PubMed  Google Scholar 

  7. • Kim D, Li AA, Perumpail BJ, Gadiparthi C, Kim W, Cholankeril G, et al. Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States. Hepatology. 2019;69(3):1064-74. (This manuscript describes the etiology specific mortality rates of HCC among minority populations in the United States over the period from 2007 to 2016. Mortality rates for NAFLD and alcohol cirrhosis and HCC have increased while HBV-cirrhosis related mortality have declined.)

    Article  PubMed  Google Scholar 

  8. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335-49.e15.

    Article  PubMed  Google Scholar 

  9. Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer. 2020;147(2):317–30.

    Article  CAS  PubMed  Google Scholar 

  10. Chen JG, Egner PA, Ng D, Jacobson LP, Muñoz A, Zhu YR, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila). 2013;6(10):1038–45.

    Article  CAS  Google Scholar 

  11. Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol. 2018;24(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  12. Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park JH, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 2013;34(8):1800–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med. 2008;148(11):820–6.

    Article  PubMed  Google Scholar 

  14. Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol. 2011;26(Suppl 1):131–7.

    Article  PubMed  Google Scholar 

  15. Chan SL, Wong VW, Qin S, Chan HL. Infection and cancer: the case of hepatitis B. J Clin Oncol. 2016;34(1):83–90.

    Article  CAS  PubMed  Google Scholar 

  16. World Health Organization. Global hepatitis report. 2017. Available at: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ Accessed April 17, 2021.

  17. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.

    Article  CAS  PubMed  Google Scholar 

  18. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223–38.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl 19):102–7.

    Article  PubMed  Google Scholar 

  20. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol. 1986;18(4):301–7.

    Article  CAS  PubMed  Google Scholar 

  21. Lee H, Lee H, Cho Y, Oh K, Ki M. Changes in seroprevalence of hepatitis B surface antigen and epidemiologic characteristics in the Republic of Korea, 1998–2013. Epidemiol Health. 2015;37:e2015055.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550–7.

    Article  PubMed  Google Scholar 

  23. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.

    Article  CAS  PubMed  Google Scholar 

  24. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24(3):346–53.

    Article  PubMed  Google Scholar 

  25. Yimnoi P, Posuwan N, Wanlapakorn N, Tangkijvanich P, Theamboonlers A, Vongpunsawad S, et al. A molecular epidemiological study of the hepatitis B virus in Thailand after 22 years of universal immunization. J Med Virol. 2016;88(4):664–73.

    Article  PubMed  Google Scholar 

  26. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310(9):974–6.

    Article  CAS  PubMed  Google Scholar 

  27. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. https://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=CHN&commit=OK. Accessed April 18, 2021.

  28. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. https://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=KOR. Accessed April 18, 2021.

  29. Baatarkhuu O, Uugantsetseg G, Munkh-Orshikh D, Naranzul N, Badamjav S, Tserendagva D, et al. Viral Hepatitis and Liver Diseases in Mongolia. Euroasian J Hepatogastroenterol. 2017;7(1):68–72.

    Article  PubMed  PubMed Central  Google Scholar 

  30. World Health Organization. Viral hepatitis in Mongolia: situation and response. https://apps.who.int/iris/bitstream/handle/10665/208324/9789290617396_eng.pdf?sequence=1&isAllowed=y. Accessed April 17, 2021.

  31. Ork V, Woodring J, Shafiqul Hossain M, Wasley A, Nagashima S, Yamamoto C, et al. Hepatitis B surface antigen seroprevalence among pre- and post-vaccine cohorts in Cambodia, 2017. Vaccine. 2019;37(35):5059–66.

    Article  PubMed  PubMed Central  Google Scholar 

  32. •• Le MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH. Chronic Hepatitis B Prevalence among foreign-born and U.S.-born adults in the United States, 1999-2016. Hepatology. 2020;71(2):431-43. (This manuscript describes the prevalence of chronic Hepatitis B among US and foreign-born adults over two decades. There prevalence of HBV infection was unchanged over this period of time. US-born individuals had lower prevalence of HBV infection and exposure with higher vaccine-mediated immunity than foreign-born persons. Prevalence of infection was highest amongnon-Hispanic Asians with very low awareness of liver disease.)

    Article  CAS  PubMed  Google Scholar 

  33. Roberts H, Kruszon-Moran D, Ly KN, Hughes E, Iqbal K, Jiles RB, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988–2012. Hepatology. 2016;63(2):388–97.

    Article  CAS  PubMed  Google Scholar 

  34. Mahale P, Torres HA, Kramer JR, Hwang LY, Li R, Brown EL, et al. Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry-based case-control study. Cancer. 2017;123(7):1202–11.

    Article  PubMed  Google Scholar 

  35. Wei L, Hou JL. The guideline of prevention and treatment for hepatitis C: a 2015 update. Zhonghua Gan Zang Bing Za Zhi. 2015;23(12):906–23.

    CAS  PubMed  Google Scholar 

  36. Qin Q, Smith MK, Wang L, Su Y, Wang L, Guo W, et al. Hepatitis C virus infection in China: an emerging public health issue. J Viral Hepat. 2015;22(3):238–44.

    Article  PubMed  Google Scholar 

  37. Dashtseren B, Bungert A, Bat-Ulzii P, Enkhbat M, Lkhagva-Ochir O, Jargalsaikhan G, et al. Endemic prevalence of hepatitis B and C in Mongolia: a nationwide survey amongst Mongolian adults. J Viral Hepat. 2017;24(9):759–67.

    Article  CAS  PubMed  Google Scholar 

  38. Wasitthankasem R, Posuwan N, Vichaiwattana P, Theamboonlers A, Klinfueng S, Vuthitanachot V, et al. Decreasing hepatitis C virus infection in Thailand in the past decade: evidence from the 2014 national survey. PLoS One. 2016;11(2):e0149362.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014;60(4):691–8.

    Article  PubMed  Google Scholar 

  40. Surveillance for viral hepatitis - United States, 2017. https://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm. Accessed July 6, 2021. 2019.

  41. Kruszon-Moran D, Paulose-Ram R, Denniston M, McQuillan G. Viral Hepatitis Among Non-Hispanic Asian Adults in the United States, 2011–2014. NCHS Data Brief. 2015;225:1–8.

    Google Scholar 

  42. Tien A, Sahota A, Yang SJ, Balbuena R, Chang M, Lim C, et al. Prevalence and characteristics of chronic hepatitis C among Asian Americans are distinct from other ethnic groups. J Clin Gastroenterol. 2020.

  43. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol. 2014;25(8):1526–35.

    Article  CAS  PubMed  Google Scholar 

  45. World Health Organization. (2018). Global status report on alcohol and health 2018: executive summary. World Health Organization. https://apps.who.int/iris/handle/10665/312318.

  46. Yang S-S. Alcoholic liver disease in the Asian-Pacific Region with high prevalence of chronic viral hepatitis. Journal of Medical Ultrasound. 2016;24(3):93–100.

    Article  Google Scholar 

  47. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537–64.

    Article  CAS  PubMed  Google Scholar 

  48. Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–82.

    Article  PubMed  Google Scholar 

  49. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.

    Article  PubMed  Google Scholar 

  50. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828-37.e2.

    Article  PubMed  Google Scholar 

  51. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–30.

    Article  CAS  PubMed  Google Scholar 

  52. Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, et al. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther. 2019;50(7):809–21.

    Article  CAS  PubMed  Google Scholar 

  53. • Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389-98. (This meta-analysis describes the incidence and prevalence of NAFLD in Asia over 2 decades. The rising incidence and prevalence is quite significant with poor outcomes from liver cancer.)

    Article  PubMed  Google Scholar 

  54. Jeong EH, Jun DW, Cho YK, Choe YG, Ryu S, Lee SM, et al. Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do. Korea Clin Mol Hepatol. 2013;19(3):266–72.

    Article  PubMed  Google Scholar 

  55. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006;21(1 Pt 1):138–43.

    Article  PubMed  Google Scholar 

  56. Imaizumi H, Takahashi A, Tanji N, Abe K, Sato Y, Anzai Y, et al. The association between sleep duration and non-alcoholic fatty liver disease among japanese men and women. Obes Facts. 2015;8(4):234–42.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22(9):1141–5.

    Article  CAS  PubMed  Google Scholar 

  58. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–73.

    Article  PubMed  Google Scholar 

  59. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012;27(10):1555–60.

    Article  PubMed  Google Scholar 

  60. • M Tobari E Hashimoto M Taniai Y Ikarashi K Kodama T Kogiso et al 2019 Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: not uncommon and not always benign J Gastroenterol Hepatol 34 8 1404 1410. (Describes the concept of NASH in lean patients in Asian.)

    Article  CAS  PubMed  Google Scholar 

  61. Alvarez CS, Graubard BI, Thistle JE, Petrick JL, McGlynn KA. attributable fractions of nonalcoholic fatty liver disease for mortality in the United States: results from the third National Health and nutrition examination survey with 27 years of follow-up. Hepatology. 2020;72(2):430–40.

    Article  CAS  PubMed  Google Scholar 

  62. Golabi P, Paik J, Hwang JP, Wang S, Lee HM, Younossi ZM. Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. Liver Int. 2019;39(4):748–57.

    Article  PubMed  Google Scholar 

  63. •• Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-905. (This manuscript showed the pivotal results of the combination atezolizumab and bevacizumab improving surival in patients with liver cancer compared to sorafenib. This established the new first-line therapy for HCC.)

    Article  CAS  PubMed  Google Scholar 

  64. •• Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450-6. (This manuscript describes immune microenvironment of NASH and NASH-HCC with aberrant T cells infiltration and activation. It provided the first large meta-analysis that NASH-HCC patients do not derive the same benefit with immunotherapy compared to patients with viral etiology-HCC.)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. • Haber PK, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled Trials (2002–2020). Gastroenterology. 2021. (Describes the similar results to Pfister et al. with viral-HCC have better response to immunothearpy.)

  66. •• Z Wang EG Aguilar JI Luna C Dunai LT Khuat CT Le et al 2019 Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade Nat Med 25 1 141 151. (Describes the obesity paradox in may cancer types.)

    Article  CAS  PubMed  Google Scholar 

  67. Silvestris N, Argentiero A, Natalicchio A, D’Oronzo S, Beretta GD, Acquati S, et al. Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. ESMO Open. 2021;6(3):100153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J Clin Oncol. 2021;39(18):2037–48.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Division of Medical Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA

    Nguyen H. Tran

Authors
  1. Nguyen H. Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nguyen H. Tran.

Ethics declarations

Conflict of Interest

Nguyen H. Tran has received honoraria from QED Therapeutics for service as a consultant.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Palliative Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tran, N.H. Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications. Curr Oncol Rep 24, 187–193 (2022). https://doi.org/10.1007/s11912-021-01160-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-021-01160-5

Keywords

Search

Navigation